This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic
subjects at risk for lung cancer (based on smoking history, lung function testing, and
atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest
computerized tomography (CAT) scans and examinations of their airways with a bronchoscope at
the start of the trial and after 6 months on treatment. Compensation will be provided to the
subject after completing the trial.